FX Empire Logo Español Português Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence c ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the Zacks Growth Style Score (part of the Zacks Style ...

Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic. The EC approval is based on pivotal data from the Phase III OCARINA II trial, which showed non-inferior levels of ...

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). "With this approval, CIDP patients in the U.S. will have access to the fi ...

Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator ...

Value Score Growth Score Momentum Score VGM Score How Style Scores Work with the Zacks Rank But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from. Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy. Stock to Watch: Halozyme Therapeutics (HALO) Momentum investors should take note of this Medical stock. H ...

However, Halozyme has clarified that its EPS guidance does not consider the impact of potential future share repurchases. Year to date, shares of HALO have rallied 39.2% against the industry's 3.8% decline. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 37.7%. Halozyme Therapeutics' (HALO ...

It has been about a month since the last earnings report for Halozyme Therapeutics (HALO) . Shares have added about 8.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Halozyme's Q1 Earnings Bea ...

文章核心观点 - 公司获得一项新的欧盟专利,涵盖其ENHANZE rHuPH20产品,该专利将保护公司的核心技术至2029年3月 [1][2][3] - 这项新专利将惠及公司所有现有和未来的ENHANZE许可合作伙伴,增强公司的竞争优势和产品安全性 [2][3] - 公司预计将能够维持其与强生公司达成的DARZALEX SC在欧盟的原有特许权使用费率,直至2029年专利到期 [6][7] - 公司其他ENHANZE许可协议的特许权使用费率也不会受到影响,维持公司整体财务预期和稳定性 [8][9] - 公司第一季度的特许权使用费收入同比增长21%,全年预计在500-525百万美元区间 [10] 公司相关 - 公司获得一项新的欧盟专利,涵盖其ENHANZE rHuPH20产品,该专利将保护公司的核心技术至2029年3月 [1][2][3] - 这项新专利将惠及公司所有现有和未来的ENHANZE许可合作伙伴,增强公司的竞争优势和产品安全性 [2][3] - 公司预计将能够维持其与强生公司达成的DARZALEX SC在欧盟的原有特许权使用费率,直至2029年专利到期 [6][7] - 公司其他ENHANZE许可协议的特许权使用费率也不会受到影响,维持公司整体财务预期和稳定性 [8][9] - 公司第一季度的特许权使用费收入同比增长21%,全年预计在500-525百万美元区间 [10] 行业相关 - 公司ENHANZE技术被多家领先制药公司如罗氏、武田、辉瑞、强生、艾伯维、礼来、Bristol-Myers Squibb等用于开发皮下给药制剂 [4] - 公司从这些合作伙伴的7款商业化产品中获得特许权使用费收入 [5]

SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be val ...